- Roth Capital initiated coverage of Unicycive Therapeutics (NASDAQ:UNCY) with a Buy rating and $13.50 price target.
- Analyst Elemer Piros says that the Company could submit a marketing application to the FDA for Renasorb to treat hyperphosphatemia in chronic kidney disease, or CKD, in “about a year.”
- The analyst also believes that Renasorb has the potential to become “a dominant player in the kidney disease market.”
- Unicycive started trading on NASDAQ in July. It offered 5 million units at $5/unit.
- Price Action: UNCY shares closed up 14% at $3.05 on Monday.
EXCLUSIVE: Meet The Company Offering Mardi Gras NFTs For Bathroom, Bar Access And Helping Grow Web3 In New Orleans
A new collection of non-fungible tokens (NFTs) will offer holders access to bathrooms and bars during the Mardi Gras activities in New Orleans.
The NFTs will also provide additional benefits and could help launch New Orleans as a Web3 hub.
